Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2274-2025

DASH SARS-CoV-2 & Flu A/B Test Recall

DASH SARS-CoV-2 & Flu A/B Test Model/Catalog Number: SG-0006 combination COVID-19 and Flu test. Each DASH SARS-CoV-2 & Flu A/B Test is individually pouched and labeled. The tests are provided to users in quantities of 10 per kit. Used on the DASH instrument.

FDA recall Class II

Ongoing

FDA lists this Class II recall for DASH SARS-CoV-2 & Flu A/B Test. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2274-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jun 25, 2025
FDA report date
Aug 13, 2025
Quantity in commerce
710 units
Distribution
See key details
FDA cause
Process control

What is being recalled?

DASH SARS-CoV-2 & Flu A/B Test Model/Catalog Number: SG-0006 combination COVID-19 and Flu test. Each DASH SARS-CoV-2 & Flu A/B Test is individually pouched and labeled. The tests are provided to users in quantities of 10 per kit. Used on the DASH instrument.

Affected model & UDI checker

Search the exact identifiers published for Z-2274-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
SG-0006DASH SARS-CoV-2 & Flu A/B TestCheck source noticeNot specified
Not specifiedDASH SARS-CoV-2 & Flu A/B TestCheck source notice00850063063036
FDA code information

Lot Code: Lot: BB02 UDI: (01)00850063063036(17)260220(10)BB02 Expiration Date: 20 Feb. 2026 Lot Code: Lot: BB03 UDI: (01)00850063063036(17)260220(10)BB03 Expiration Date: 20 Feb. 2026

View the original FDA recall notice

Why was this product recalled?

Due to manufacturing error, assay test may result in missed diagnosis or delay of treatment. (Potential false negative result)

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Nuclein, LLC take?

On June 25, 2025, Nuclein, LLC issued a Urgent: Medical Device Recall notification to affected customers. On July 8, 2025 an updated notification was issued via E.Mail. a. Review your inventory of DASH SARS-CoV-2 & Flu A/B Tests to confirm the quantity of Lot BB02 or BB03 that you have remaining. b. Suspend the use and quarantine the affected lot of DASH SARS-CoV-2 & Flu A/B Tests; Nuclein will replace any unused affected product. c. Review all results of the product lots detailed in Section 6, below, to identify potentially erroneous diagnosis, except in those cases where alternative confirmation was obtained. d. Forward this information to all individuals and departments within your organization using the product information detailed in Section 6. If you are not the end user, forward this notice to the product end user. e. Complete the Acknowledgement and Receipt Form below and either email the completed form to [email protected] or mail to the address identified in the Acknowledgement and Receipt Form. f. Return the affected tests that you have remaining; Nuclein Customer Support will follow up with you on the details of returning or destroying the affected product.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology